Technologies

Aptamers, short structured single-stranded oligonucleotides binding at high affinity to a given target protein, are selected from large combinatorial libraries through repeated cycles of incubation of the library with the target, recovery and amplification of target-bound oligonucleotides (SELEX technology, Systematic Evolution of Ligands by EXponential enrichment). SELEX can be applied to select aptamers against a known target protein or against a specific cell phenotype, without any prior knowledge of the specific target, leading to new biomarkers discovery.

The Biocrystal Facility, a large multidisciplinary laboratory established at the Institute of Molecular Biology and Pathology (IBPM) of CNR, in collaboration with the Biochemistry Department of Sapienza University aims at supporting the italian scientists and the pharmaceutical companies in the research to find new drug and vaccine against the endemic and epidemic diseases through structure-based drug design.

The dramatic global health emergency due to the SARS-CoV-2 pandemic requires new diagnostic devices capable of identifying the presence of virus particles in patient biological samples. In this direction, the development of an innovative low-cost test, which provides the result within a few minutes, which is reproducible and which can reveal the direct presence of even a few viral particles, would be of fundamental importance for the monitoring and containment of the pandemic.

The assessment of bio-humoral markers beyond clinical evaluation would allow a more comprehensive pheno/endotyping of patients affected by chronic inflammatory diseases. Therapy personalization would require a profile of the mediators that are relevant in the disease pathogenesis and that well correlate with prognosis. Currently, the measurement of multiple biomarkers is not included in patient evaluation because it has high costs,  requires centralized laboratories, experienced personnel and bulky equipment and is time-consuming.

The virtual dynamic docking, carried out in the MOLBD3 lab of the Institute of Biophysics, allows the identification of new drugs through the structural information deriving from the study of target proteins, responsible for some human pathologies. In particular, we screen drugs or small molecules (commercial/own libraries) against known protein sites, surface cavities, surfaces of protein-protein interactions (fixed/rigid hotspots) or structural transition states (dynamic hotspots).

VisLab laboratory of IMM possesses a latest generation Raman micro-spectroscope equipped for vibrational measurements with high spatial and spectral resolution, at controlled temperature and in fast-imaging. The apparatus can be used to collect information and chemico-physical maps without the need for sample preparation and alteration, therefore for non-destructive studies and in operating conditions.

We developed a procedure aimed at simultaneously treating thousands of C.elegans model organisms, from eggs to old adult, in liquid, in 96- or 384-well plates. This procedure can be used to perform drug and toxicological screening of millions of compounds, in very small volumes and on millions of animals. Thanks to easy handling, semi-automatic analysis can be performed using plate readers or High Content Screening instruments.

Our idea come from the improving of the traceability technique in agro-food fisheries industries through the application of omics technologies in microbiota studies.  These latter would be capable of exploiting the huge pool of biological molecules contained in fishery resources (e.g. nucleic acids, proteins, metabolites) and use them as a powerful tools for the identification and reconstruction of fishery history, from the sea to the table.

In the last years, genetics played a strategic role in the identification of therapeutic targets for complex diseases. Genetic studies identified thousands of variants contributing to disease onset and/or to the influence of measurable features (phenotypes) impacting health. The mechanism of action by which they modulate diseases and phenotypes is still unknown for the vast majority.

Detection devices for the presence of molecules of interest (analytes) enjoyed a renewed burst with the introduction of biological components (biosensors). Their high specificity is often used in various fields, from environmental monitoring and biomedicine to the protection and promotion of agri-food products. However, the high cost of production and the lack of compatibility with mass sampling (high-throughput) sometimes limit their use.

Integrative omics has posed new challenges in modern precision medicine, particularly in oncology, including i) the identification of new tumor markers for early, precise, and non-invasive diagnostics, and ii) the discovery of innovative molecular targets for therapeutic applications. Our studies on medulloblastoma, a highly malignant childhood tumor, have contributed to identifying RNA molecules that meet these criteria.

In our recent publication we identified a group of  bladder cancer-specific ncRNA, called T-UCRs that are the most up-regulated in bladder cancer patient samples compared with normal bladder urothelium.

It enables a systemic and evolutionary development of people, organisations and territories by overcoming the criticality of traditional approaches, which get stuck because of rationalistic reductions in complexity, as well as lack of motivation. This responds to the social sustainability needs highlighted by the UN 2030 agenda. The methodology is based on 3 pillars:

We have identified the presence of the poorly characterized precursor proNGF-A in human tissues, deposited its coding nucleotide sequence (GenBank MH358394) and demonstrated its neuroprotective and neurotrophic activity in vitro and in vivo. We inserted mutations into the native molecule, identified through computational analysis, which allow proNGF-A production by eukaryotic expression systems, through a method currently validated on a laboratory scale.

Severe asthma or chronic obstructive pulmonary disease (COPD) are nowadays associated with a poor response to corticosteroids which led to the use of high-dose with consequent improved onset of side effects. The use of nanotechnologies can represent an innovative approach for the effective treatment of both asthma and COPD. The development of new nano-formulations involving the use of nanomaterials and specifically tailored to be inhaled offers numerous advantages over conventional inhaled dosage forms.